18 November 2022 : Original article
Altered Serum Bile Acid Profile Associated with Chronic Allograft Dysfunction in Kidney Transplant Recipients
Yamei Li1ACDE, Hua Zhang23CFG, Xinhua Dai1BC, Yunfei An
1BD, Yi Li1AD, Lin Yan1EF, Yunying Shi4EF, Jiwen Fan1BC, Xingxin Gong1BDF, Lei Zhang1D, Yuangao Zou1F, Lanlan Wang1AG, Yangjuan Bai1ADE*
DOI: 10.12659/AOT.937974
Ann Transplant 2022; 27:e937974
Table 2 Serum BAs subgroup concentrations and ratios in HCs and KTRs with different allograft function.
| HC | STA | CAD1 | CAD2 | P | |
|---|---|---|---|---|---|
| 15 BAs (ng/mL) | 1311.9 (864.5–1715.6) | 1370.4 (950.5–2200.2) | 1505.4 (1072.2–2706.1) | 1044.5 (673.0–1866.3) | 0.126 |
| Unconj.BAs (ng/mL) | 465.9 (257.9–777.3) | 333.6 (164.0–581.0) | 360.3 (182.5–778.9) | 127.1 (75.6–324.2) * | 0.002 |
| Conj.BAs (ng/mL) | 748.2 (448.9–1006.2) | 960.1 (612.3–1691.4) | 1137.6 (650.4–2008.5)* | 855.5 (571.5–1465.0) | 0.026 |
| G-conj.BAs (ng/mL) | 670.6 (392.6–940.5) | 860.7 (574.0–1514.8) | 918.4 (568.0–1743.1) | 653.3 (444.8–1210.3) | 0.031 |
| T-conj.BAs (ng/mL) | 57.0 (36.0–88.7) | 80.0 (43.6–180.1) | 139.2 (52.8–207.1)* | 144.8 (94.5–286.2)* | 0.001 |
| PBAs (ng/mL) | 845.2 (449.4–1228.4) | 1012.9 (652.8–1584.5) | 1298.3 (778.7–2122.5)* | 877.1 (488.9–1623.1) | 0.034 |
| Unconj.PBAs (ng/mL) | 238.2 (95.3–443.2) | 188.7 (97.5–408.3) | 238.1 (96.2–653.7) | 87.8 (41.9–266.3)& | 0.031 |
| Conj.PBAs (ng/mL) | 538.0 (322.9–784.8) | 829.7 (454.8–(1381.4)* | 897.0 (536.3–1622.9)* | 762.7 (421.7–1211.4) | 0.006 |
| G-conj.PBAs (ng/mL) | 483.9 (287.0–716.2) | 737.9 (416.9–1198.5)* | 755.7 (481.2–1436.1)* | 598.3 (326.3–952.2) | 0.009 |
| T-conj.PBAs (ng/mL) | 44.1 (29.9–72.3) | 73.0 (39.0–163.4)* | 130.2 (47.7–177.8)* | 137.6 (82.9–248.0)* | <0.001 |
| SBAs (ng/mL) | 403.6 (252.8–536.7) | 312.2 (193.9–484.2) | 300.9 (120.6–475.2) | 171.0 (73.8–359.5)* | 0.008 |
| Unconj.SBAs (ng/mL) | 173.9 (124.0–312.8) | 121.6 (61.4–205.0)* | 110.8 (49.5–207.2) | 36.7 (20.4–92.9) * | <0.001 |
| Conj.SBAs (ng/mL) | 165.3 (107.9–232.3) | 178.5 (104.6–286.1) | 134.2 (73.4–284.4) | 104.1 (45.6–253.6) | 0.324 |
| G-conj.SBAs (ng/mL) | 157.9 (94.5–219.9) | 171.3 (93.5–277.5) | 128.1 (70.8–278.3) | 93.1 (42.2–238.4) | 0.298 |
| T-conj.SBAs (ng/mL) | 8.7 (5.1–16.2) | 7.8 (3.6–14.4) | 6.5 (3.1–12.8) | 7.5 (2.9–19.6) | 0.675 |
| SBAs/PBAs | 0.48 (0.35–0.68) | 0.30 (0.14–0.47)* | 0.22 (0.10–0.40)* | 0.20 (0.11–0.28)* | <0.001 |
| Conj./Unconj.BAs | 1.85 (0.84–2.65) | 3.07 (1.79–5.57)* | 2.70 (1.12–6.12) | 5.64 (2.97–10.93)* | <0.001 |
| CA/CDCA | 0.34 (0.24–0.63) | 0.25 (0.14–0.37) | 0.44 (0.18–0.76) | 0.45 (0.24–0.85)# | 0.017 |
| DCA/CA | 2.00 (0.42–4.70) | 0.20 (0.04–2.75)* | 0.06 (0.01–0.61)* | 0.06 (0.20–0.58)* | <0.001 |
| LCA/CDCA | 0.03 (0.01–0.10) | 0.03 (0.008–0.08) | 0.01 (0.004–0.03)* | 0.02 (0.006–0.03) | 0.013 |
| TCA/CA | 0.15 (0.06–0.45) | 0.45 (0.16–0.85)* | 0.31 (0.08–1.26) | 1.07 (0.73–6.26) * | <0.001 |
| GCA/CA | 1.74 (0.85–4.30) | 4.20 (1.95–7.92)* | 2.29 (0.92–7.92) | 4.70 (3.56–15.92)* | 0.002 |
| TCDCA/CDCA | 0.23 (0.11–0.66) | 0.43 (0.18–0.86) | 0.44 (0.17–1.20) | 1.75 (0.91–3.34) * | <0.001 |
| GCDCA/CDCA | 2.76 (1.14–5.12) | 3.69 (1.82–7.83) | 3.30 (1.38–6.57) | 7.51 (3.44–14.04) * | 0.011 |
| GDCA/DCA | 0.58 (0.37–0.99) | 1.01 (0.48–1.85)* | 0.69 (0.37–1.59) | 0.96 (0.47–1.77) | 0.045 |
| TDCA/DCA | 0.07 (0.03–0.15) | 0.15 (0.07–0.36)* | 0.19 (0.08–0.38)* | 0.36 (0.15–0.52)* | <0.001 |
| GLCA/LCA | 0.71 (0.39–1.14) | 0.37 (0.23–0.90)* | 0.38 (0.15–0.70)* | 0.28 (0.00–0.43)* | <0.001 |
| TLCA/LCA | 0.04 (0.02–0.08) | 0.03 (0.01–0.05) | 0.02 (0.01–0.07) | 0.03 (0.02–0.08) | 0.010 |
| G-unconj. – glycine unconjugated; T-conj. – taurine-conjugated; * # & | |||||